Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Agilent Technologies

Apple

AbbVie

Accenture Plc

Automatic Data Processing

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Brookfield Infrastructure

Blackrock Inc

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

CME Group

Canadian National Railway Company

I express frustration with the constant negativity surrounding the idea that beating the market is impossible for the average investor. I share my personal success in beating the market in 2023, with a time-weighted return of 28.02%. I emphasize the importance of buying high-quality companies at fair prices and holding them for the long term, while also highlighting the power of compounding dividends.

How I Beat The Market Again In 2023

Allstate

Incyte

Eli Lilly

Merck

Moderna

Viatris

The calendar just flipped to 2024 — and investors already have their favorite S&P 500 stocks. And none of them are the Big Tech giants that dominated.

7 Stocks Are Taking Off Already — And The Year Just Started

Boeing

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Intel

Johnson & Johnson

Coca-Cola

McDonald's

Microsoft

NIKE

Procter & Gamble

Verizon

Walgreens

Walmart

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: JNJ, AMGN, KO, CSCO, CVX, IBM, DOW, MMM, VZ, and WBA. They only averaged a 4.49% annual yield, as prices. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged 10.25%-22.59%, topped by CVX 1/2/24.

January Dogs Of The Dow: 2 Buyable, 6 Watchable

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines today announced key advancements across its clinical pipeline and generative AI platform, including its first patient dosed in GB-0895, progress in the phase 1 study for GB-0669, and an expansion of its collaboration agreement with Amgen. Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company's strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Mo.

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference

Duke Energy

NextEra Energy

PepsiCo

Southern Company

AT&T

It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.

Revenge of the Boring Stocks! Dividends Are Sexy Again.

THOUSAND OAKS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P.

AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen Inc (NASDAQ:AMGN, ETR:AMG) stock is poised to move higher in 2024 on a thesis its Phase II drug AMG133 for obesity will report positive data, according to Jefferies analysts.   In an update to clients, the analysts raised their price target on Amgen stock to $345 per share, from $310, on expectations of positive Phase II data for AMG133 in 2024 as well as preparations for a move to Phase III, which would start in 2025 and set up for a drug launch in 2027-28.

Amgen analysts boost target price on obesity drug data outlook

Kinder Morgan

UnitedHealth Group

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

There Are Only 5 Dow Stocks I Wouldn't Buy in 2024

In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Novo Nordisk

Pfizer

Things could hardly have gone worse for healthcare investors this year.

Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.

It's time for followers of the Dogs of the Dow stock-picking strategy to rebalance their portfolios.

What Are the Dogs of the Dow for 2024?

Amgen Inc. AMGN said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and Drug Administration. A CRL means the application will not be approved in its current form.

Amgen's NDA for Lumakras cancer treatment resulted in complete response letter

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif. , Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS® (sotorasib).

AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)

AstraZeneca

BioMarin Pharmaceutical

Bristol-Myers

Blueprint Medicines

Karuna Therapeutics Inc

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Gilead Sciences

Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech.

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone'

News for Amgen Stock (AMGN)